Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Voyager Therapeutics (VYGR) Current Assets (2016 - 2025)

Voyager Therapeutics' Current Assets history spans 11 years, with the latest figure at $202.7 million for Q4 2025.

  • For Q4 2025, Current Assets fell 26.78% year-over-year to $202.7 million; the TTM value through Dec 2025 reached $202.7 million, down 26.78%, while the annual FY2025 figure was $202.7 million, 26.78% down from the prior year.
  • Current Assets for Q4 2025 was $202.7 million at Voyager Therapeutics, down from $219.6 million in the prior quarter.
  • Across five years, Current Assets topped out at $409.1 million in Q1 2024 and bottomed at $124.5 million in Q4 2022.
  • The 5-year median for Current Assets is $223.7 million (2025), against an average of $234.2 million.
  • The largest annual shift saw Current Assets crashed 41.66% in 2021 before it skyrocketed 156.78% in 2023.
  • A 5-year view of Current Assets shows it stood at $136.7 million in 2021, then fell by 8.92% to $124.5 million in 2022, then soared by 156.78% to $319.7 million in 2023, then decreased by 13.41% to $276.8 million in 2024, then dropped by 26.78% to $202.7 million in 2025.
  • Per Business Quant, the three most recent readings for VYGR's Current Assets are $202.7 million (Q4 2025), $219.6 million (Q3 2025), and $227.9 million (Q2 2025).